Business Wire

VOOPOO

4.7.2022 09:17:05 CEST | Business Wire | Press release

Share
VOOPOO Unveils 3 New Products, Telling Story of Its 8-year Entrepreneurship Journey in 30 Minutes

VOOPOO’s 2022 "More Than Infinity " virtual product launch was held on June 29, 2022, where VOOPOO took 30 minutes to review its brand story during the past 8 years since its founding, expounding the connection between the “infinity symbol” and the brand spirit and demonstrating its commitment to creating infinite new possibilities using technology in 3 chapters. Meanwhile, the event was highlighted by 3 POD products featuring VOOPOO’s most cutting-edge technology.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220629005586/en/

A very important theme at the virtual event was telling the growth story of VOOPOO since its founding 8 years ago. Evolving from an atomization chip solution provider to today’s industry leader of open electronic atomization, VOOPOO has driven the positive development of the industry through a series of disruptive innovations while undergoing its own brand metamorphosis. In addition, since VOOPOO started the globalization strategy last year, it has opened branches in the United States, the United Kingdom, Indonesia, Germany, France, Canada, and Malaysia, and will open more in the future to strengthen localized operation in the local market. VOOPOO has also insisted on strengthening its global influence in the global electronic atomization field by setting up brand flagship stores and launching APPs in more regions.

As another essential part of the event, VOOPOO released the three latest Pod products, of which two V-series products, namely VMATE E and VMATE Infinity Edition, were unveiled for the first time. Both products are equipped with the newly upgraded cartomizer, using the 5A freshness seal technology to lock the fresh taste and aroma of the e-liquid, while the Fresnel lens texture design can effectively reduce the e-liquid’s exposure to light, preserving the fresh taste for users. The material of the cartridge is specially added with silver ions with 99%+ effective antibacterial performance.

The third product Drag Q which was previously released came back with a new CMF Infinity Edition. As a POD product, Drag Q has subverted the industry's understanding of POD products with its expert-level performance in intelligent pressure control and taste restoration. At the virtual launch, the VOOPOO global brand ambassador also explained in detail the core drive of VOOPOO’s leapfrog development, i.e., the investment in “user-centered” R&D. So far, VOOPOO has launched three pioneering atomization platforms catering to different users -- PNP, TPP, ITO , and has developed two GENE chips for different product functions -- GENE AI and GENE TT . It is with the continuous optimization and innovation in atomization technology that VOOPOO wins trust and support of consumers.

Infinite connections: join hands with 100,000+ customers and 50,000,000+ fans to build an electronic atomization culture

The last chapter was dedicated to the customers and millions of fans who marched forward hand in hand with VOOPOO. In the past 8 years, VOOPOO has cooperated closely with more than 100,000 offline outlets, and has won more and more consumers with high-quality products and continuous market investment. Its market achievements are the evidence of mutual benefit and win-win cooperation with partners. On a global scale, more than 50 million users have become loyal fans of VOOPOO. They not only spur VOOPOO to continue to create products that are ahead of the times but also become part of the electronic atomization culture in the VOOPOO ecosystem. VOOPOO announced that the first flagship stores, being part of the VOOPOO ecosystem, will open in the UK and Indonesia for close interaction with VOOPOO fans.

VOOPOO took 30 minutes to demonstrate the connection between VOOPOO’s development strategy, innovative spirit, brand culture and the infinity symbol, while the 3 newly launched products will be worthy of the expectations of the market and the industry.

About VOOPOO

VOOPOO is a leading brand of open pod system and has rapidly risen through DRAG products, which have been widely acclaimed globally in a short period of time. VOOPOO focuses on building two core technology platforms of [Chip] and [Atomization]. VOOPOO has creatively developed GENE.AI, GENE.TT and other chips. In addition, VOOPOO independently developed three Atomization Platforms, which are TPP,PNP,ITO, aiming at differentiated users. VOOPOO has four major product series - ARGUS, DRAG, VINCI, and V-series(Doric). VOOPOO will continue to develop more national markets in the future, aiming to build one of the most influential global brands.

The original source-language text of this announcement is the official, authoritative version. Translations are provided as an accommodation only, and should be cross-referenced with the source-language text, which is the only version of the text intended to have legal effect.

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Kubota Vision Inc. Signs Supply and Licensing Agreement with Laboratoires KÔL for Stargardt Disease Treatment Candidate Under Compassionate Use4.5.2026 17:16:00 CEST | Press release

Kubota Vision Inc. (“Kubota Vision”), a wholly-owned subsidiary of Kubota Pharmaceutical Holdings Co., Ltd. (Minato-ku, Tokyo, Japan) announced signing of a Supply and Licensing Agreement with Laboratoires KÔL (Clermont-Ferrand, France) for the provision of a Stargardt disease (STGD1) treatment candidate under compassionate use authorization. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260414590785/en/ The purpose of this Agreement is for Kubota Vision and KÔL to collaborate on providing “Emixustat” for treatment of Stargardt Disease (STGD1) through compassionate use authorization in France. Kubota Vision will exclusively manufacture and supply Emixustat final products to KÔL and KÔL will have exclusive rights to distribute Emixustat in France under compassionate use access. Ryo Kubota, Chairman, President, and CEO of Kubota Pharmaceutical Holdings, stated, “We are extremely pleased to enter into this Agreement with Labor

Incentive Market Set to Surpass $80B by 2030s — IMA Launches Tools to Help the Industry Keep Pace4.5.2026 16:28:00 CEST | Press release

With combined business spend on loyalty, employee recognition, and channel incentives projected to exceed $80 billion by the 2030s, the incentive industry is entering a period of rapid scale and strategic pressure. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260422729016/en/ In response, the Incentive Marketing Association (IMA) launched a new suite of resources designed to help incentive professionals navigate an environment that’s becoming more specialized, fragmented, and central to business performance. “It’s not just more money coming in—it’s more complexity,” said Vince Chiofolo, President of the Incentive & Engagement Solution Providers (IESP). “Buyers are demanding programs that evolve fast, integrate deeply, and feel personal at scale. These new tools were built for that.” IMA’s Suite of Tools Includes: New Industry Report — Inside the Incentive Buyer’s Mind Drawn from insights of 50+ program owners, the report f

Tigo Energy Breaks Global Growth Benchmark; Boosts U.S. Energy Feature in Predict+4.5.2026 15:00:00 CEST | Press release

Advanced energy prediction platform adds real-time energy pricing for North American Independent System Operator (ISO) customers, accelerates meters-connected growth. Tigo Energy, Inc. (NASDAQ: TYGO) (“Tigo” or “Company”), a leading provider of intelligent solar and energy solutions, today announced that the Predict+ platform now offers integrated real-time spot market pricing for ISO customers in the United States. Predict+ provides utilities with deep insights into grid demand, renewable generation, and energy market dynamics, enhancing the precision, scalability, and robustness of energy forecasting to up to 97.5% accuracy through machine learning and artificial intelligence. For energy providers, Predict+ helps streamline operations, reduce volatility, and maximize performance. Predict+ empowers utility operators to adapt to real-world demand challenges when balancing renewable and baseload generation sources, particularly during extreme weather events and market disruptions. On th

Airship Announces 2026 Elevate Customer Experience Award Winners4.5.2026 15:00:00 CEST | Press release

Southwest Airlines, The Economist, and OneFootball among brands recognized at Elevate’26 Customer Experience Summit for setting the standard in mobile-first and AI-centered customer experiences Airship, the mobile-first customer experience company, today announced the winners of the 2026 Elevate Customer Experience Awards. Global brand leaders from The Economist, Southwest Airlines, and OneFootball were among those honored at the Elevate’26 Customer Experience Summit. The Elevate Awards spotlight global companies that have developed exceptional mobile-first customer experiences for their customers, created innovative campaigns, leveraged AI agents to reach new levels of productivity, and achieved real business results. "Evolving mobile-first consumer behaviors and unprecedented advancements in AI are driving a seismic shift that is reshaping how brands interact with their customers," said Brett Caine, CEO, Airship. "The 2026 Elevate Award winners aren’t just adapting, they’re leading t

Alnylam to Present New Analyses at Heart Failure 2026 Underscoring Consistent Clinical Profile of Vutrisiran in ATTR-CM4.5.2026 14:30:00 CEST | Press release

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced it will present new data analyses for vutrisiran in patients with the cardiomyopathy of wild-type or hereditary transthyretin-mediated amyloidosis (ATTR-CM) at Heart Failure 2026, a scientific congress of the European Society of Cardiology, taking place May 9-12, 2026, in Barcelona, Spain. ATTR-CM is a heterogeneous and rapidly progressive disease, and patients often present with complex clinical profiles. At Heart Failure 2026, Alnylam will present multiple new analyses from the Phase 3 HELIOS-B study of vutrisiran, which continue to support its use as a first-line treatment for patients with ATTR-CM, and further characterize its clinical profile across patients with a high disease burden, and in the context of concomitant therapies. Vutrisiran is the first and only transthyretin (TTR) silencer for ATTR-CM that delivers rapid knockdown of TTR at the source. Additional analyses being pr

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye